Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Options net pounds 150,000 for Girolami

Gail Counsell
Thursday 16 June 1994 18:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

SIR Paul Girolami, chairman of Glaxo, yesterday made almost pounds 150,000 through the exercise of options held under the company's share scheme, writes Gail Counsell.

Glaxo said that Sir Paul, 68, who has just announced his retirement from the drug group, had exercised options on 71,600 shares in the company at pounds 3.78 a share.

He had then sold the same number of shares at pounds 5.86 a share.

The shares represent only a relatively small part of his total holding in the group, however. Glaxo's most recent set of accounts show Sir Paul had 590,848 options as at 30 June last year. At the same date he also owned 457,904 shares outright, worth pounds 2.7m at yesterday's price.

Sir Paul, who will cease all group executive responsibilities at the end of next month, but who will not step down from the board until November, is one of the UK's highest paid businessmen.

He earned more than pounds 1.4m in 1993, including a pounds 410,400 payment under Glaxo's rolling, four-year, performance-related bonus scheme.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in